Minerva Neurosciences | NERV - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Adma Biologics USD 390.32M 86.99M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Alterity Therapeutics Limited AUD 36.21M 18.58M 2025-12
AstraZeneca USD 47.33B 1.33B 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Cipla INR 344.32B 15.13B 2026-03
Clal Biotechnology ILS 121.41M 4.62M 2023-12
Compugen USD 95.35M 7.38M 2026-03
CSL USD 18.66B 2.75B 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Grifols EUR 6.21B 133.12M 2025-12
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
J&J USD 84.97B 3.78B 2026-06
Merck USD 45.88B 6.73B 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novavax USD -144.76M 17.01M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Roche Holding CHF 32.69B 1.11B 2026-06
Sanofi EUR 72.81B 1.1B 2026-03
Takeda JPY 7.77T 129.5B 2026-03
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12